造血干细胞移植后的免疫治疗：协同效应的潜力。
Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects.
作者信息
Bouchlaka Myriam N, Redelman Doug, Murphy William J
机构信息
Department of Microbiology & Immunology, University of Nevada, Reno, NV, USA.
出版信息
Immunotherapy. 2010 May;2(3):399-418. doi: 10.2217/imt.10.20.
Abstract
Hematopoietic stem cell transplantation (HSCT) is a particularly important treatment for hematologic malignancies. Unfortunately, following allogeneic HSCT, graft-versus-host disease, immunosuppression and susceptibility to opportunistic infections remain among the most substantial problems restricting the efficacy and use of this procedure, particularly for cancer. Adoptive immunotherapy and/or manipulation of the graft offer ways to attack residual cancer as well as other transplant-related complications. Recent exciting discoveries have demonstrated that HSCT could be expanded to solid tissue cancers with profound effects on the effectiveness of adoptive immunotherapy. This review will provide a background regarding HSCT, discuss the complications that make it such a complex treatment procedure following up with current immunotherapeutic strategies and discuss emerging approaches in applying immunotherapy in HSCT for cancer.
摘要
造血干细胞移植（HSCT）是血液系统恶性肿瘤的一种特别重要的治疗方法。不幸的是，在异基因HSCT之后，移植物抗宿主病、免疫抑制以及对机会性感染的易感性仍然是限制该治疗方法疗效和应用的最主要问题，尤其是对于癌症而言。过继性免疫治疗和/或对移植物的操控为攻克残留癌症以及其他与移植相关的并发症提供了途径。最近令人兴奋的发现表明，HSCT可扩展至实体组织癌症，对过继性免疫治疗的有效性产生深远影响。本综述将提供有关HSCT的背景知识，讨论使其成为如此复杂治疗程序的并发症，接着介绍当前的免疫治疗策略，并探讨在HSCT治疗癌症中应用免疫治疗的新方法。
相似文献
1
Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects.造血干细胞移植后的免疫治疗：协同效应的潜力。
Immunotherapy. 2010 May;2(3):399-418. doi: 10.2217/imt.10.20.
2
Immunobiology of allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植的免疫生物学
Annu Rev Immunol. 2007;25:139-70. doi: 10.1146/annurev.immunol.25.022106.141606.
3
[Allogeneic hematopoietic stem cell transplantation for solid tumors in the United States: a review].[美国实体瘤的异基因造血干细胞移植：综述]
Nihon Rinsho. 2003 Sep;61(9):1619-34.
4
Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.在小鼠异基因造血干细胞移植中，抗CD4抗体治疗与供体淋巴细胞输注相结合可改善移植物抗宿主病，同时保留移植物抗肿瘤效应。
Cancer Sci. 2017 Oct;108(10):1967-1973. doi: 10.1111/cas.13346. Epub 2017 Aug 29.
5
Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.同种异体免疫治疗以优化移植物抗肿瘤效应：概念和争议。
Expert Rev Hematol. 2010 Jun;3(3):301-14. doi: 10.1586/ehm.10.29.
6
Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.非清髓性造血干细胞移植（NST）治疗人类恶性肿瘤：从动物模型到临床实践。
Cancer Treat Res. 2002;110:113-36. doi: 10.1007/978-1-4615-0919-6_6.
7
Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions.异基因造血细胞移植作为实体瘤的免疫治疗：现状与未来方向。
J Immunother. 2005 Jul-Aug;28(4):281-8. doi: 10.1097/01.cji.0000165354.19171.8f.
8
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
9
Graft-Versus-Solid-Tumor Effect: From Hematopoietic Stem Cell Transplantation to Adoptive Cell Therapies.移植物抗实体瘤效应：从造血干细胞移植到过继细胞疗法。
Stem Cells. 2022 Jun 22;40(6):556-563. doi: 10.1093/stmcls/sxac021.
10
Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies.血液系统恶性肿瘤患者异基因造血干细胞移植后的过继性免疫治疗
Transfus Med Rev. 2015 Oct;29(4):259-67. doi: 10.1016/j.tmrv.2015.07.001. Epub 2015 Jul 10.
引用本文的文献
1
Challenges in the management of operable triple-negative breast cancer in a survivor of the B-cell acute lymphoblastic leukemia: a case report.B 细胞急性淋巴细胞白血病幸存者可手术三阴性乳腺癌的管理挑战：一例报告
Front Oncol. 2024 May 16;14:1404706. doi: 10.3389/fonc.2024.1404706. eCollection 2024.
2
Worked to the bone: antibody-based conditioning as the future of transplant biology.精疲力竭：基于抗体的调理作为移植生物学的未来。
J Hematol Oncol. 2022 May 19;15(1):65. doi: 10.1186/s13045-022-01284-6.
3
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.单独或联合 ASCT 使用 CAR T 细胞鸡尾酒治疗伴有 TP53 改变的侵袭性 B 细胞淋巴瘤的结果。
Signal Transduct Target Ther. 2022 Apr 11;7(1):101. doi: 10.1038/s41392-022-00924-0.
4
A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature.造血干细胞移植患者中 SARS-CoV-2 感染的特征：系统文献复习。
Curr Oncol. 2022 Jan 13;29(1):337-349. doi: 10.3390/curroncol29010030.
5
Monocyte Maturation Mediators Upregulate CD83, ICAM-1 and MHC Class 1 Expression on Ewing's Sarcoma, Enhancing T Cell Cytotoxicity.单核细胞成熟介质上调尤文肉瘤细胞表面 CD83、ICAM-1 和 MHC Ⅰ类分子的表达，增强 T 细胞的细胞毒性。
Cells. 2021 Nov 8;10(11):3070. doi: 10.3390/cells10113070.
6
Hospitalization rates for complications due to systemic therapy in the United States.美国因全身治疗导致的并发症住院率。
Sci Rep. 2021 Apr 1;11(1):7385. doi: 10.1038/s41598-021-86911-x.
7
No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease.在晚期尤文肉瘤患者中，HLA 错配与 HLA 匹配的同种异体干细胞移植后的生存无差异。
Bone Marrow Transplant. 2021 Jul;56(7):1550-1557. doi: 10.1038/s41409-020-01200-x. Epub 2021 Jan 29.
8
Lipid Complications after Hematopoietic Stem Cell Transplantation (HSCT) in Pediatric Patients.儿童造血干细胞移植（HSCT）后的脂质并发症。
Nutrients. 2020 Aug 19;12(9):2500. doi: 10.3390/nu12092500.
9
Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia.靶向组蛋白去乙酰化酶调节移植物抗宿主病和移植物抗白血病。
Int J Mol Sci. 2020 Jun 16;21(12):4281. doi: 10.3390/ijms21124281.
10
Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy.肿瘤免疫学与免疫治疗中的β-肾上腺素能信号传导
Crit Rev Immunol. 2019;39(2):93-103. doi: 10.1615/CritRevImmunol.2019031188.
本文引用的文献
1
Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.癌症的过继性免疫疗法：新一代基因工程免疫细胞。
Tissue Antigens. 2009 Oct;74(4):277-89. doi: 10.1111/j.1399-0039.2009.01336.x.
2
Rapamycin or tacrolimus alone fails to resist cardiac allograft accelerated rejection mediated by alloreactive CD4(+) memory T cells in mice.雷帕霉素或他克莫司单独应用不能抵抗同种异体反应性 CD4(+)记忆 T 细胞介导的小鼠心脏移植加速排斥反应。
Transpl Immunol. 2010 Feb;22(3-4):128-36. doi: 10.1016/j.trim.2009.09.003. Epub 2009 Sep 13.
3
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.硼替佐米、他克莫司和甲氨蝶呤用于预防来自人类白细胞抗原不匹配无关供者的低强度预处理异基因干细胞移植后的移植物抗宿主病。
Blood. 2009 Oct 29;114(18):3956-9. doi: 10.1182/blood-2009-07-231092. Epub 2009 Aug 27.
4
Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units.脐带血移植后的复发风险：2单位移植受者的移植物抗白血病效应增强
Blood. 2009 Nov 5;114(19):4293-9. doi: 10.1182/blood-2009-05-220525. Epub 2009 Aug 25.
5
Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease.在无关供体移植中，主要组织相容性复合体I类链相关基因A的供体-受体错配会导致急性移植物抗宿主病的发病率增加。
Blood. 2009 Oct 1;114(14):2884-7. doi: 10.1182/blood-2009-05-223172. Epub 2009 Aug 4.
6
Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo.体内自然杀伤细胞缺失自我识别的基因和抗体介导的重编程
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84. doi: 10.1073/pnas.0901653106. Epub 2009 Jun 26.
7
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.1-7F9的临床前特性研究，1-7F9是一种新型的人抗KIR受体治疗性抗体，可增强自然杀伤细胞介导的肿瘤细胞杀伤作用。
Blood. 2009 Sep 24;114(13):2667-77. doi: 10.1182/blood-2009-02-206532. Epub 2009 Jun 24.
8
The promise and potential pitfalls of chimeric antigen receptors.嵌合抗原受体的前景与潜在风险。
Curr Opin Immunol. 2009 Apr;21(2):215-23. doi: 10.1016/j.coi.2009.02.009. Epub 2009 Mar 25.
9
Adoptive cell therapy for the treatment of patients with metastatic melanoma.过继性细胞疗法治疗转移性黑色素瘤患者
Curr Opin Immunol. 2009 Apr;21(2):233-40. doi: 10.1016/j.coi.2009.03.002. Epub 2009 Mar 21.
10
Graft-versus-host disease.移植物抗宿主病
Lancet. 2009 May 2;373(9674):1550-61. doi: 10.1016/S0140-6736(09)60237-3. Epub 2009 Mar 11.
Zotero 插件